136 related articles for article (PubMed ID: 20212450)
1. DNA methylation of HOXD3 as a marker of prostate cancer progression.
Kron KJ; Liu L; Pethe VV; Demetrashvili N; Nesbitt ME; Trachtenberg J; Ozcelik H; Fleshner NE; Briollais L; van der Kwast TH; Bapat B
Lab Invest; 2010 Jul; 90(7):1060-7. PubMed ID: 20212450
[TBL] [Abstract][Full Text] [Related]
2. Association of tissue promoter methylation levels of APC, TGFβ2, HOXD3 and RASSF1A with prostate cancer progression.
Liu L; Kron KJ; Pethe VV; Demetrashvili N; Nesbitt ME; Trachtenberg J; Ozcelik H; Fleshner NE; Briollais L; van der Kwast TH; Bapat B
Int J Cancer; 2011 Nov; 129(10):2454-62. PubMed ID: 21207416
[TBL] [Abstract][Full Text] [Related]
3. Correlation of ERG expression and DNA methylation biomarkers with adverse clinicopathologic features of prostate cancer.
Kron K; Liu L; Trudel D; Pethe V; Trachtenberg J; Fleshner N; Bapat B; van der Kwast T
Clin Cancer Res; 2012 May; 18(10):2896-904. PubMed ID: 22452941
[TBL] [Abstract][Full Text] [Related]
4. Correlation of HOXD3 promoter hypermethylation with clinical and pathologic features in screening prostate biopsies.
Chen LN; Rubin RS; Othepa E; Cer C; Yun E; Agarwal RP; Collins BT; McGeagh K; Pahira J; Bandi G; Kowalczyk K; Kumar D; Dritschilo A; Collins SP; Bostwick DG; Lynch JH; Suy S
Prostate; 2014 May; 74(7):714-21. PubMed ID: 24847526
[TBL] [Abstract][Full Text] [Related]
5. GBX2 Methylation Is a Novel Prognostic Biomarker and Improves Prediction of Biochemical Recurrence Among Patients with Prostate Cancer Negative for Intraductal Carcinoma and Cribriform Architecture.
Jeyapala R; Savio AJ; Olkhov-Mitsel E; Kamdar S; Zhao F; Cuizon C; Liu RSC; Zlotta A; Fleshner N; van der Kwast T; Bapat B
Eur Urol Oncol; 2019 May; 2(3):231-238. PubMed ID: 31200836
[TBL] [Abstract][Full Text] [Related]
6. Methylation of PITX2, HOXD3, RASSF1 and TDRD1 predicts biochemical recurrence in high-risk prostate cancer.
Litovkin K; Joniau S; Lerut E; Laenen A; Gevaert O; Spahn M; Kneitz B; Isebaert S; Haustermans K; Beullens M; Van Eynde A; Bollen M
J Cancer Res Clin Oncol; 2014 Nov; 140(11):1849-61. PubMed ID: 24938434
[TBL] [Abstract][Full Text] [Related]
7. Evaluation and prognostic significance of ACAT1 as a marker of prostate cancer progression.
Saraon P; Trudel D; Kron K; Dmitromanolakis A; Trachtenberg J; Bapat B; van der Kwast T; Jarvi KA; Diamandis EP
Prostate; 2014 Apr; 74(4):372-80. PubMed ID: 24311408
[TBL] [Abstract][Full Text] [Related]
8. A urine-based DNA methylation assay, ProCUrE, to identify clinically significant prostate cancer.
Zhao F; Olkhov-Mitsel E; Kamdar S; Jeyapala R; Garcia J; Hurst R; Hanna MY; Mills R; Tuzova AV; O'Reilly E; Kelly S; Cooper C; ; Brewer D; Perry AS; Clark J; Fleshner N; Bapat B
Clin Epigenetics; 2018 Nov; 10(1):147. PubMed ID: 30470249
[TBL] [Abstract][Full Text] [Related]
9. DNA methylation of PITX2 predicts poor survival in men with prostate cancer.
Vasiljević N; Ahmad AS; Carter PD; Fisher G; Berney DM; Foster CS; Cuzick J; Lorincz AT
Biomark Med; 2014; 8(9):1143-50. PubMed ID: 25402584
[TBL] [Abstract][Full Text] [Related]
10. Aberrant Promoter Methylation of Protocadherin8 (PCDH8) in Serum is a Potential Prognostic Marker for Low Gleason Score Prostate Cancer.
Lin YL; Li YL; Ma JG
Med Sci Monit; 2017 Oct; 23():4895-4900. PubMed ID: 29026066
[TBL] [Abstract][Full Text] [Related]
11.
Barry KH; Mohanty K; Erickson PA; Wang D; Shi J; Rose G; Cellini A; Clark K; Ambulos N; Yin J; Yan L; Poulin M; Meyer A; Zhang Y; Bentzen SM; Burke A; Hussain A; Berndt SI
Genes (Basel); 2020 Dec; 12(1):. PubMed ID: 33374332
[TBL] [Abstract][Full Text] [Related]
12. Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer.
Bañez LL; Sun L; van Leenders GJ; Wheeler TM; Bangma CH; Freedland SJ; Ittmann MM; Lark AL; Madden JF; Hartman A; Weiss G; Castaños-Vélez E
J Urol; 2010 Jul; 184(1):149-56. PubMed ID: 20478579
[TBL] [Abstract][Full Text] [Related]
13. Biopsy and radical prostatectomy pathological patterns influence Prostate cancer gene 3 (PCA3) score.
De Luca S; Passera R; Bollito E; Milillo A; Scarpa RM; Papotti M; Coda R; Randone DF
Anticancer Res; 2013 Oct; 33(10):4657-62. PubMed ID: 24123045
[TBL] [Abstract][Full Text] [Related]
14. Aberrant methylation of protocadherin 17 and its clinical significance in patients with prostate cancer after radical prostatectomy.
Lin YL; Xie PG; Wang L; Ma JG
Med Sci Monit; 2014 Aug; 20():1376-82. PubMed ID: 25091018
[TBL] [Abstract][Full Text] [Related]
15. Presence of high grade tertiary Gleason pattern upgrades the Gleason sum score and is inversely associated with biochemical recurrence-free survival.
Turker P; Bas E; Bozkurt S; Günlüsoy B; Sezgin A; Postacı H; Turkeri L
Urol Oncol; 2013 Jan; 31(1):93-8. PubMed ID: 21316989
[TBL] [Abstract][Full Text] [Related]
16. DNA methylation of the PITX2 gene promoter region is a strong independent prognostic marker of biochemical recurrence in patients with prostate cancer after radical prostatectomy.
Weiss G; Cottrell S; Distler J; Schatz P; Kristiansen G; Ittmann M; Haefliger C; Lesche R; Hartmann A; Corman J; Wheeler T
J Urol; 2009 Apr; 181(4):1678-85. PubMed ID: 19233404
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Significance of Percentage and Architectural Types of Contemporary Gleason Pattern 4 Prostate Cancer in Radical Prostatectomy.
Choy B; Pearce SM; Anderson BB; Shalhav AL; Zagaja G; Eggener SE; Paner GP
Am J Surg Pathol; 2016 Oct; 40(10):1400-6. PubMed ID: 27379821
[TBL] [Abstract][Full Text] [Related]
18. PITX2 methylation: a novel and effective biomarker for monitoring biochemical recurrence risk of prostate cancer.
Jiang Q; Xie M; He M; Yan F; Chen M; Xu S; Zhang X; Shen P
Medicine (Baltimore); 2019 Jan; 98(1):e13820. PubMed ID: 30608394
[TBL] [Abstract][Full Text] [Related]
19. [Impact of Gleason score on biochemical recurrence free survival after radical prostatectomy with positive surgical margins].
Roux V; Eyraud R; Brureau L; Gourtaud G; Senechal C; Fofana M; Blanchet P
Prog Urol; 2017; 27(8-9):467-473. PubMed ID: 28576421
[TBL] [Abstract][Full Text] [Related]
20. Histopathological variables and biomarkers enhancer of zeste homologue 2, Ki-67 and minichromosome maintenance protein 7 as prognosticators in primarily endocrine-treated prostate cancer.
Tolonen TT; Tammela TL; Kujala PM; Tuominen VJ; Isola JJ; Visakorpi T
BJU Int; 2011 Nov; 108(9):1430-8. PubMed ID: 21592298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
